STAT Plus: What we learned about the business of telemedicine from Amwell and GoodRx’s IPO filings September 2, 2020 Los Angeles Biotechnology Network News Los Angeles Biotech News Comments Off on STAT Plus: What we learned about the business of telemedicine from Amwell and GoodRx’s IPO filings The filings offer a window into the finances of telemedicine. Among the takeaways: Revenues aren’t growing as quickly as use, and Teladoc is still on top.